UNSPSC 51112702: Cisplatin

This classification denotes a radiosensitizing agent and platinum compound with the molecular formula 2Cl. Pt.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q20Q21Q62J, chemically known as platinum(ii), diamminedichloro-, trans- but more generally known as cisplatin, which bears US NIH Compound Identifier 2767. European Medicines Agency schedules Cisplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07483MIG.

UNSPSC 51112702 Cisplatin, a Commodity code, designates a chemotherapy agent purchased by state and local health systems, departments of corrections, and state employee health plans. State and local governments procure cisplatin as a formulary pharmaceutical for cancer treatment programs, typically through bulk purchasing arrangements with pharmaceutical wholesalers, group purchasing organizations, or direct manufacturer contracts. The single recent opportunity shows state health agencies exploring direct-to-manufacturer procurement models to manage costs and supply chain efficiency, moving away from traditional pharmacy benefit manager and wholesaler intermediaries.

The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about vendors' capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside existing PBM, GPO, and wholesaler arrangements. The RFI, posted in late March 2026, was exploratory in nature — designed to inform the state's future procurement strategy rather than issue a formal competitive solicitation — and did not specify award values, budget ranges, set-aside designations, or binding timelines. Recent activity under this code is limited; the available record shows no other state or local solicitations for cisplatin or related oncology pharmaceuticals during the recent period, suggesting either sparse transaction volume through formal procurement channels or purchasing conducted through standing cooperative agreements and wholesaler framework contracts not separately advertised as standalone RFPs or RFQs.